<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Given the rarity of follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL) in children, there is limited data on which to base treatment recommendations </plain></SENT>
<SENT sid="1" pm="."><plain>Herein, we report our institutional experience of using rituximab with multiagent chemotherapy for pediatric FL </plain></SENT>
<SENT sid="2" pm="."><plain>Six pediatric patients were diagnosed with FL from 2000 to 2009 </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received rituximab in combination with <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, and <z:chebi fb="0" ids="8382">prednisone</z:chebi> (R-CHOP) for varying durations </plain></SENT>
<SENT sid="4" pm="."><plain>Five of the six patients remain in remission with a median follow-up of 31 months </plain></SENT>
<SENT sid="5" pm="."><plain>Larger randomized trials are indicated to establish the efficacy of this regimen for pediatric FL patients </plain></SENT>
</text></document>